InTrOduCTIOn
Atrial fibrillation (AF) burden is increasing worldwide 1 and constitutes a progressive disease in most cases. 2 3 The arrhythmia carries a high risk of complications such as thromboembolic events, heart failure and coronary events. Anticoagulation therapy used to reduce stroke risk increases bleeding disposition. Chronic AF patterns (persistent, long-standing persistent and permanent AF) appear to be associated with an increased thromboembolic risk compared with paroxysmal AF (PAF) as shown by a recent meta-analysis. 4 Early AF recurrence and persistent AF have been associated with a higher mortality and an increased risk of stroke and heart failure in the community compared with paroxysmal types or lack of recurrence after an initial episode. 5 In patients, disease progression seems to be accompanied by a higher risk of adverse events. 6 7 Furthermore, mortality is increased with longer episodes of AF, which may be confounded by clinical characteristics in patients with non-PAF. 8 9 Current guidelines categorise AF into paroxysmal, persistent, longstanding persistent and permanent based on duration and termination of episodes. In addition, new onset disease represents a specific category. The relevance of AF patterns in clinical practice has not been fully defined. Further, the progression rate of AF and its clinical correlates remain unclear. A prior publication addressed predictors for AF progression in patients with PAF. 10 Hypertension, age, transient ischaemic attack (TIA) or stroke, chronic obstructive pulmonary disease and heart failure (HATCH score) were identified as predictors of AF progression in PAF. The score replicated only modestly in independent cohorts. 8 11 Therefore, a systematic examination of indicators of AF progression across the spectrum of AF types is required. Further data are needed relating AF type to cardiovascular outcomes in clinical practice. Therefore, we used the PREFER in AF (PREvention oF thromboembolic events-European Registry in Atrial Fibrillation) registries to examine the clinical impact of AF type and progression on prognosis and to elucidate predictors of disease progression.
MeThOds study sample
We analysed two similarly structured contemporary European registries on epidemiology, management and outcome in all-comers with AF, the PREFER in AF and its Prolongation study. The study design and primary results of PREFER in AF have been published previously. 12 In brief, the PREFER in AF registry enrolled 7243 patients with AF at least 18 years across seven European countries from 2012 to 2014. At 1 year, information was collected by a questionnaire with a last follow-up in January 2014. Enrolment took place at 461 sites, which were predominantly cardiology practices and hospitals. A total of 6412 patients completed the follow-up. From 22 patients, AF type at baseline was missing, leaving 6390 patients for analysis.
The PREFER in AF prolongation registry is an extension of the PREFER in AF registry that enrolled 3597 patients from June 2014 to May 2015 and including sites that had already participated in the PREFER in AF registry (n=412). They had to be on non-vitamin K antagonist oral anticoagulant treatment at enrolment. As data on AF type were available at baseline and follow-up in the PREFER in AF prolongation registry, the primary analysis was performed in this cohort. A total of 3223 patients had complete 1-year follow-up data at the last follow-up (June 2016). As data on AF type at baseline were missing in 13 patients, the analysis was performed in 3210 patients. The PREFER in AF dataset was used for validation using available information on baseline AF type.
Clinical variables
All patients had AF documented by ECG and diagnosed by a physician. AF pattern information was in accordance with the European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines. 13 As there was a small number of patients with longstanding persistent AF (n=132 in PREFER in AF prolongation; n=516 in PREFER in AF), this category was combined with permanent AF for analysis. A total of 55 patients in the PREFER in AF prolongation and 103 in the PREFER in AF study were classified as permanent AF but showed sinus rhythm on study ECG and were categorised as persistent AF. Sensitivity analyses confirmed that the results did not change markedly after reclassification of these individuals. We performed additional analyses in patients with AF onset <12 months.
Outcomes
AF type at a 1-year follow-up was the primary outcome. We assumed a disease progression if patients with PAF at baseline were classified as persistent or permanent AF at follow-up and if patients with persistent AF on enrolment were diagnosed with permanent AF after 1 year. Prevalent cardiovascular disease incorporated coronary heart disease, peripheral arterial disease and myocardial infarction.
We evaluated the following disease outcomes: ischaemic stroke/TIA/arterial embolism, coronary events (acute coronary syndrome/coronary revascularisation), heart failure (physician diagnosis and/or reduced left ventricular ejection fraction) and major bleeding (cerebrovascular bleeding, major gastrointestinal or other bleeding events requiring hospitalisation or blood transfusion). AF type and outcomes were assessed at the follow-up.
Local Ethics Committees in Austria, Germany, Switzerland, Italy, Spain, France and UK provided their approval as required by national regulations. All participants provided written, informed consent. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
statistical analyses
Data were analysed separately for the PREFER in AF prolongation and PREFER in AF studies. Complete case analysis was performed, after we had formally tested whether data were missing completely at random. Data are presented as mean ±SD for continuous variables, or median (25th/75th percentile) for skewed variables, and as number (percentage) for discrete variables. We compared the overall proportion of individuals with progression to patients stable or less advanced disease state by McNemar's test. We performed logistic regression analyses to relate baseline variables to progression of AF over 1 year in PREFER in AF prolongation. A logistic stepwise variable selection model as implemented in SAS was applied to identify the strongest predictors of AF progression. All baseline variables were permitted to enter the model. The C-statistic as implemented in SAS proc logistic using ROC statement (the area under the receiver operating characteristic (ROC) curve) was calculated to understand the discriminatory ability of the combination of all selected clinical baseline variables to predict AF progression. We compared the discriminatory ability of our model with the previously reported HATCH score using its variables hypertension, age, TIA or stroke, chronic obstructive pulmonary disease and heart failure. 6 AF progression at follow-up was related to outcomes using logistic regression analyses. Furthermore, unadjusted and multivariable-adjusted regression analyses were performed to relate baseline AF type to 1-year outcomes, adjusted for age, sex and country. Comparison of persistent and permanent AF to PAF was used as the reference. Patients with prevalent heart failure at baseline were excluded from analyses on the incident condition.
We performed sensitivity analyses for regression analyses using PAF versus non-PAF types combined. For these analyses, sinus rhythm was not permitted to enter the stepwise model. Results are based on PREFER in AF prolongation data if not stated otherwise.
SAS software V.9.4 was used for statistical computations. A two-tailed significance threshold of 0.05 indicated statistical significance.
resulTs baseline patient characteristics
In table 1 baseline characteristics of the PREFER in patients with AF prolongation are detailed by type of AF. Patients with permanent AF were older, had a longer AF duration and accumulated cardiovascular risk factors such as hypertension, diabetes, dyslipidaemia, chronic pulmonary disease and valvular heart disease. Individuals with permanent AF also had the highest proportion of a history of thromboembolic events and major bleedings. Almost half of the patients with persistent AF had a cardioversion in the year prior to enrolment (p<0.05 compared with other AF patterns). Clinical characteristics were similar in the PREFER in AF registry (online supplementary table 1). The distribution of AF type at baseline for the total PREFER in AF prolongation study and for the subgroup of patients with AF duration <1 year (n=1738) are shown in the online supplementary figure 1. Among patients with AF duration <1 year, approximately half (n=555, 52%) had non-paroxysmal types of AF at baseline.
AF progression at a 1-year follow-up was observed in 506 (16.5%) patients. Figure 1A shows that 242 (19%) individuals with PAF and 264 (34.4%) with persistent AF had a progression. In patients with a new diagnosis of AF <1 year, the progression rate was 20.4% (n=217) (figure 1B). Whereas the majority of patients with PAF remained in PAF, similar proportions of patients with persistent AF remained in the same category or showed progression over 1 year. Among patients who transitioned into permanent AF after 1 year, 12.8% were on antiarrhythmic drug therapy, 15.4% had undergone cardioversion and 8.3% had an ablation therapy.
A regression of AF type was observed in persistent AF patients (n=115, 32%).
Arrhythmias and sudden death Type of AF and outcomes
In unadjusted logistic regression analyses, we identified statistically significant associations of AF type with incident heart failure (OR 1.80, 95% CI 1.06 to 3.07; p=0.029), which lost statistical significance after multivariable adjustment (table 2). In the larger PREFER in AF registry, there was an association of similar magnitude for both permanent and persistent AF versus PAF (online supplementary table 
Figure 1
The number and proportion of AF types at baseline and at a 1-year follow-up are provided: (A) the total PREFER in AF prolongation study (n=3063) and (B) patients with AF diagnosed <1 year (n=1063). Slightly lower numbers compared with the baseline table are due to missing information of AF type at follow-up. AF, atrial fibrillation; PREFER, PREvention oF thromboembolic events-European Registry.
2). Further, permanent AF compared with PAF was inversely related to coronary events, but no signal was seen in PREFER in AF. showed a positive association with progression. These variables and diabetes mellitus were selected as the strongest predictors of AF progression by logistic stepwise selection using all variables presented in table 3 ( figure 2 ). The C-statistic of the selected variables combined was 0.64 and significantly differed from the results when using the HATCH score, C-statistic 0.52 (p=0.0001). Results from stepwise selection models in patients with AF progression <1 year are shown in the online supplementary figure 2. The selected variables were comparable with the total cohort except for hyperthyroidism, heart valve dysfunction and diabetes that did not enter the model. 
Predictors of AF progression

Arrhythmias and sudden death
weaker due to the small number of patients with PAF progression to more permanent types (n=242). AF duration in PAF was not associated with progression.
dIsCussIOn
Main findings
In our AF cohort, the majority of patients were in the non-PAF group. Even in individuals with an AF duration of <1 year, almost 50% had persistent or permanent AF. The progression rate over 1 year was substantial. Permanent AF was associated with new development of heart failure, and AF was associated with coronary events. We identified clinical parameters that were associated with AF progression, but there is a clear need to identify better markers for AF progression.
AF type and progression
It is recognised that clinical characteristics of patients differ across AF type. Patients with permanent AF are older and show more, possibly AF-related, complications such as a history of thromboembolic events, heart failure or bleeding besides the longer AF duration. The majority of patients presenting in clinical practice are in the non-PAF group. We further saw that when first diagnosed, AF did not necessarily evolve from PAF. Among patients with a diagnosis of AF within 12 months, 47% were classified as non-PAF. In both groups, patients with a long-standing diagnosis of AF and with AF duration <1 year, we observed a substantial progression. In the latter, one-fifth of the patients developed chronic forms of AF in 1 year. A higher proportion of individuals in persistent AF progressed compared with patients with PAF.
We also observed a regression in AF type from persistent to PAF. Some patients may be defined as persistent while presenting with similar AF burden and duration as others who are defined as paroxysmal. 11 AF regression is probably a biological fact and has been reported earlier. 12 The relatively large proportion of patients that was classified as persistent AF at baseline and PAF after 1 year, however, may be due to cardioversion therapy prior to baseline that automatically classifies patients into persistent AF, whereas later on, paroxysms of AF that terminate spontaneously may occur.
Predictors AF progression
In multivariable models, we identified several clinical predictors of AF progression. Among these, heart failure has been related to AF incidence and progression. 6 13 It is pathophysiologically plausible that structural and functional cardiac changes contribute to the initiation and perpetuation of AF. Heart failure has been reported as an indicator of AF progression in the Euro Heart Survey.
14 In this cohort, the HATCH score was developed in patients with PAF. 15 In the present study, we extend this finding towards a cohort across the spectrum of PAF and persistent AF and identified the following additional predictors: the duration HRs and 95% CIs are provided. Data are based on 3063 individuals with complete follow-up information. *Patients with heart failure at baseline were excluded from analyses (n=797). AF, atrial fibrillation; PREFER, PREvention oF thromboembolic events-European Registry; TIA, transient ischaemic attack.
of AF, diabetes, hyperthyroidism and valvular disease. In our cohort, the HATCH score replicated poorly as has been reported in other studies. 2 8 These findings underline that with current variables it is difficult to predict AF progression.
Of note, the time since AF diagnosis was inversely related to progression, indicating a faster dynamic in change early after the first diagnosis of AF, with a possible stabilisation of disease phenotype later during the disease course. A higher progression rate early during PAF has been reported in the Canadian Registry of Atrial Fibrillation, but with a much lower percentage, that is, 8.6%.
14 The absolute rate of AF progression will depend on patient characteristics as well as on the intensity of rhythm control treatment.
Diabetes and hyperthyroidism as well as valvular heart disease constitute treatable conditions. It seems sensible to consider good management of these conditions to slow AF progression, especially in patients undergoing rhythm control therapy. Hyperthyroidism is well known in association with AF incidence and recurrence. 15 16 We can now demonstrate that it is also correlated with progression of AF type. There are two likely explanations: mechanisms triggered by hormonal imbalance that lead to AF onset also produce the substrate for AF recurrence and perpetuation of disease. 17 Furthermore, hyperthyroidism limits antiarrhythmic drug therapy, in particular with amiodarone, and may result in a higher AF progression rate. We could not confirm hypertension, TIA or stroke nor chronic obstructive pulmonary disease as strong predictors of AF progression as reported in the HATCH score. The lack of validation may be due to underlying differences in the studies. In particular, our cohort comprised a broader range of AF types and may thus not be comparable directly.
A possible correlation of progression of PAF with mortality has been reported. 3 6 We could demonstrate an association with coronary events, but not with other AF-related events, which may be limited by the comparatively small number of outcomes during the 1-year observational period.
AF type and outcome
Over the 1-year follow-up period, we observed an association for AF type with coronary events and a borderline association with heart failure incidence. For coronary events, the direction of association was inverse and only present for permanent AF compared with PAF. No significant results for persistent versus PAF were demonstrated. In addition, there was no signal of an association in PREFER in AF with more than three times the number of outcomes. Therefore, we assume that the results are spurious findings.
Similarly as discussed for AF progression, heart failure and AF are two closely inter-related diseases that share common pathophysiological pathways and perpetuate each other. 18 Hence, permanent AF may reflect a more advanced AF disease state that could be associated with manifestation of heart failure. The presence of AF could additionally worsen ventricular function as has been shown for patients with tachycardiomyopathy. 19 20 Our associations seen over 1 year were consistent in both registries; however, validation in independent cohorts is required. Ongoing clinical trials evaluating heart failure as an outcome will examine the impact of maintaining sinus rhythm on ventricular function. 21 We could not demonstrate an impact of AF pattern on thromboembolic events, but the low overall event rate observed in the PREFER registries precludes firm conclusions. A trend towards higher risk of thromboembolic events in chronic AF compared with PAF was confirmed by a meta-analysis comprising almost 100 000 patients. 4 There was substantial heterogeneity among studies and in the individual studies, the association was not uniform. For example, in large contemporary trials, such as the ROCKET-AF study, patients with persistent AF had higher thromboembolic event rates, 22 whereas in the Euro Heart Survey, there was no clear difference in event rates between PAF and persistent AF. 23 In the present study, the majority of patients received oral anticoagulation therapy and showed a low thromboembolic event rate across AF subtypes accordingly. Beyond the comparison of PAF versus more persistent types, we further had the opportunity to examine the subgroups of permanent and persistent AF in relation to outcomes. However, we could not demonstrate a gradient in associations for thromboembolic events either. In line with the recent meta-analysis, 4 we could not show an association of AF type with bleeding risk.
limitations
The number of events over the 1-year follow-up period was relatively small. However, we had good power to detect moderate to strong associations. 6 A high follow-up rate of 95% should largely eliminate bias due to incomplete information on outcomes. Inherent to the currently used AF patterns, which do not reflect the true AF burden, we might have seen different associations if the actual frequency and duration of AF episodes had been known. Interactions in the relations of the different predictors of AF progression are pathophysiologically plausible. A formal statistical testing was not performed due to the comparatively small number of cases.
Further, it needs to be considered that the current definition of AF subtypes incorporates both pathophysiological and physician's subjective assessment where psychosocial factors and management strategies may play a role. In older and sicker patients including those with heart failure AF will more likely be accepted as permanent by the treating physician and fewer attempts at restoration of sinus rhythm will be made. The AF subtype definition therefore not
Key messages
What is already known on this subject? ► Atrial fibrillation (AF) appears to be a progressive disease.
Non-paroxysmal AF has been associated with adverse outcomes. Clinical predictors of AF may exist.
What might this study add?
► This study shows that almost half of the patients with AF duration <1 year were in permanent AF. AF revealed a significant progression rate over 1 year (17%). Permanent AF was associated with increased risk of developing heart failure. Determinants of AF progression comprised AF duration, diabetes mellitus, heart failure, hyperthyroidism, sinus rhythm at baseline, cardioversion and valvular heart disease.
how might this impact on clinical practice? ► AF is a progressive disease during a comparatively short 1-year time frame which needs to be considered when treating patients with the rhythm disorder. Modifiable clinical predictors of AF progression exist and may represent targets for intervention to reduce progression rate. New, prognostically relevant patterns of AF may need to be defined.
necessarily reflects the pathophysiology of the disease course but many factors in the patient-physician interaction. Therefore, the classification is not objective and may be subject to bias. The strength of our study is that we present data in a large contemporary cohort that provides insights into AF distribution and its progression and a broad spectrum of clinically relevant outcomes using the guideline-recommended classification system.
COnClusIOn
In summary, AF is a progressive disease in most patients with a significant annual progression rate identified in two AF all-comer cohorts. Clinical predictors of progression have also been identified. Future studies need to demonstrate whether the progression rate can be reduced by targeting modifiable predictors. More importantly, it needs to be shown whether AF progression is associated with adverse events, and whether prevention of progression improves outcomes in AF and needs to be integrated into AF management.
